Skip to main content

Soligenix Announces Extension of Development Agreement with Emergent BioSolutions

January 03, 2017

Soligenix, Inc. Announced today that it has extended its development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax™ drug substance protein antigen.  RiVax™ is a vaccine candidate being developed to protect against ricin exposure.  This specific agreement will build upon process development work conducted to date in support of manufacturing scale-up that will eventually be performed in accordance with current good manufacturing practices (cGMPs) at Emergent's manufacturing facility located in Baltimore, MD.  

Learn more